Oxford Gene Technology Grants Microarray Licence to BF-BIOlabs
News Sep 29, 2008
Oxford Gene Technology (OGT) and BF-BIOlabs have announced the completion of a licensing agreement granting BF-BIOlabs access to OGT’s “Southern array patents”, the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.
The granted licence will enable BF-BIOlabs to sell arrays and provide services that include the design and production of custom-made microarrays for gene-identification, single nucleotide polymorphisms (SNP) and gene expression analysis.
Susan Sutton, Vice President Licensing (North America and Europe) at OGT, said: “OGT continues to grow its microarray licensee portfolio in Europe and this in turn will enable companies to expand their business activities and make microarray technology more accessible.”
BF-BIOlabs designs and produces custom-made microarrays for gene-identification, SNP, and gene-expression analysis, using specialized microarray production processes to achieve optimal specificity and sensitivity. In addition, BF-BIOlabs offers a full service for microarray experiments, chip readout and data analysis.
The licence will remain valid for the patents’ lifetime. Financial details were not disclosed.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019